Bavarian Nordic AS (CHIX:BAVAC) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:BAVAC Bavarian Nordic AS CHIX:BAVAC
79 GF Score
Price kr188.30
GF Value kr164.93
! 3 Warning Signs
View Full Analysis

What is Bavarian Nordic AS Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

CHIX:BAVAC
79GF Score
Bavarian Nordic AS CHIX:BAVAC
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?

Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued. The current stock price of kr188.30 is trading 14.2% above its estimated GF Value™ of kr164.93.

Key valuation signals for CHIX:BAVAC:

  • Interest Received:
  • GF Value™: kr164.93 vs. price of kr188.30 (14.2% above fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bavarian Nordic AS Business Description

Address Philip Heymans Alle 3, Hellerup, DNK, 2900
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
79GF Score

Get the complete analysis for CHIX:BAVAC

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr188.30
Price
kr164.93
GF Value